Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, Roche Holdings Ltd. deal

The companies revised provisions of their 1995 agreement involving their division of product development costs. The original agreement called for Roche to opt-in to projects at the end of Phase II

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE